SCHEMBL861910

SCHEMBL861910

COc1cc2[c]ncnc2cc1OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.53
PDGFRA P16234 1/20 0.53
KDM1A O60341 1/20 0.47
IRAK1 P51617 1/20 0.47
IRAK4 Q9NWZ3 1/20 0.47
KIT P10721 1/20 0.46
ELANE P08246 1/20 0.45
EGFR P00533 3/20 0.45
HTT P42858 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
HPGD P15428 1/20 0.45
STAT3 P40763 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TLR9 Q9NR96 2/20 0.44
TLR7 Q9NYK1 2/20 0.44
CHRNA7 P36544 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
LCK P06239 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL199450 0.84 LCK (0.41) PDGFRBPDGFRAEGFRKDM4ESMN1; SMN2
SCHEMBL6274858 0.79 EGFR (0.44) KDM1AEGFR
SCHEMBL861736 0.76 RAB9A (0.49) EGFRLMNASMN1; SMN2MEN1KMT2A
SCHEMBL14417895 0.76 KDM1A (0.58) KDM1AIRAK1IRAK4KITELANE
SCHEMBL1011705 0.76 KDM1A (0.58) KDM1AIRAK1IRAK4KITELANE
SCHEMBL197937 0.76 EGFR (0.45) PDGFRBKDM1AEGFRATM
SCHEMBL861348 0.75 MAPT (0.39) PDGFRBPDGFRAHTTKDM4EHPGD
Hydrochloric Acid SCHEMBL28084909 0.75 EGFR (0.58) PDGFRBPDGFRAKDM1AIRAK1IRAK4
SCHEMBL15404712 0.75 ENPP1 (0.43) EGFRLMNA
SCHEMBL16281244 0.74 KDM1A (0.60) PDGFRBPDGFRAKDM1AIRAK1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-04-17 US disclosed
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2014-03-20 US disclosed
US-8648066-B2 Benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture EXELIXIS, INC. (US) 2014-02-11 US disclosed
EP-2640366-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-09-25 EP disclosed
WO-2012068096-A2 BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-24 WO disclosed
EP-2432779-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2012-03-28 EP disclosed
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture EXELIXIS, INC. (US) 2010-11-25 US disclosed
WO-2010135524-A1 BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298290-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDGFRB 1294/4885PDGFRA 1516/4885KDM1A 1161/4885
US-20140107100-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDGFRB 1292/4885PDGFRA 1346/4885KDM1A 962/4885
US-20140080810-A1 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture MTOR, RICTOR, PIK3CA PDGFRB 1410/4885PDGFRA 1653/4885KDM1A 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.